A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI

People with Cystic Fibrosis (PwCF) experience frequent respiratory symptoms, including cough, mucus production and fatigue, all particularly problematic in those with advanced lung disease (ALD) [1]. CF-associated symptoms are emotionally and physically burdensome, and symptom reduction is reported as the most important outcome to PwCF [2]. In 2019 elexacaftor/tezacaftor/ivacaftor (ETI) was first approved in the United States (US) for PwCF with at least one F508del mutation. ETI has proven to significantly decrease the frequency of pulmonary exacerbations, reduce respiratory symptoms, and increase lung function in PwCF [3,4].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Short Communication Source Type: research